UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K/A

(Amendment No. 1)

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 13, 2020

EyePoint Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware	000-51122	26-2774444
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

480 Pleasant Street
Watertown, MA 02472
(Address of Principal Executive Offices, and Zip Code)

(617) 926-5000
Registrant's Telephone Number, Including Area Code

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001	**EYPT**	**The Nasdaq Stock Market LLC**

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events

On January 13, 2020, EyePoint Pharmaceuticals, Inc. (the "Company") filed a Current Report on Form 8-K to report that the Company posted an updated corporate presentation on its website at www.eyepointpharma.com. This Amendment No. 1 to Current Report on Form 8-K/A ("Amendment No. 1") is being filed to report that the Company has posted a further updated corporate presentation on its website at www.eyepointpharma.com to correct certain scrivener's errors contained in the previous version of the corporate presentation. A copy of the corrected presentation is filed herewith as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Corporate Presentation, dated January 14, 2020

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EYEPOINT PHARMACEUTICALS, INC.

Date: January 16, 2020

/s/ Nancy Lurker
Nancy Lurker
President and Chief Executive Officer

Exhibit 99.1

INVESTOR PRESENTATION

JANUARY 2020

NASDAQ: EYPT

EyePoint Pharmaceuticals

FORWARD LOOKING

EyePoint Pharmaceuticals

- SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. This presentation is intended for communication for investors only. Nothing in this presentation should be construed as promoting the use of YUTIQ®, DEXYCU® or other product candidates. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not limited to statements about our expected financial results for the fourth quarter and full fiscal year ended December 31, 2019 and longer-term financial and business goals, are forward-looking statements. Our preliminary fourth quarter and full year 2019 revenue results are preliminary and subject to adjustment in the ongoing review procedures by our independent registered public accounting firm. In addition, any financial projections and other estimates contained herein are forward-looking statements with respect to the anticipated performance of the Company. Such financial projections and estimates are as to future events and are not to be viewed as facts, and reflect various assumptions of management of the Company and are subject to significant business, financial, economic, operating, competitive and other risks and uncertainties and contingencies (many of which are difficult to predict and beyond the control of the Company) that could cause actual results to differ materially from the statements included herein. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements are risks and uncertainties inherent in our business including, without limitation: our ability to achieve profitable operations and access to needed capital; fluctuations in our operating results; our ability to successfully produce sufficient commercial quantities of YUTIQ and DEXYCU and to successfully commercialize YUTIQ and DEXYCU in the U.S.; our ability to sustain and enhance an effective commercial infrastructure and enter into and maintain commercial agreements for YUTIQ and DEXYCU; the regulatory approval and successful release of our YUTIQ line extension shorter-duration treatment for non-infectious uveitis affecting the posterior segment of the eye; potential off-label sales of ILUVIEN for non-infectious uveitis affecting the posterior segment of the eye; consequences of fluocinolone acetonide side effects for YUTIQ; consequences of dexamethasone side effects for DEXYCU; successful commercialization of, and receipt of revenues from, ILUVIEN for diabetic macular edema, or DME; Alimera's ability to obtain additional marketing approvals and the effect of pricing and reimbursement decisions on sales of ILUVIEN for DME; Alimera's ability to commercialize ILUVIEN for non-infectious uveitis affecting the posterior segment of the eye in the territories in which Alimera is licensed to do so; declines in Retisert royalties; our ability to market and sell products; the success of current and future license agreements; termination or breach of current license agreements; our dependence on contract research organizations, contract sales organizations, vendors and investigators; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; volatility of stock price; possible dilution; absence of dividends; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.

AN EMERGING LEADER IN OPHTHALMOLOGY

EyePoint Pharmaceuticals

DEXYCU (dexamethasone intraocular suspension) 9%

Postoperative inflammation following ocular surgery

0.18 mg YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg

Chronic non-infectious uveitis affecting the posterior segment of the eye

- Transitioned into commercial growth company with the launches of YUTIQ® and DEXYCU® in Q1 2019
- Pipeline focused on innovative therapies improving standard of care in areas of unmet need, including wet AMD
- Focused on organic and inorganic product growth leveraging proprietary technologies and select product acquisition to build top-line revenue and expand pipeline
- Strategic focus to become go-to partner for commercialization in ophthalmology
- Veteran executive team with deep experience in commercial product launches and clinical development

PRODUCT PIPELINE

EYEPOINT PHARMACEUTICALS

Program	Preclin.	Phase 1	Phase 2	Phase 3	Commercial	Rights
DEXYCU® post-operative inflammation					Launched/J-Code In-Place	WW
YUTIQ® three-year treatment for chronic non-infectious uveitis affecting the posterior segment					Launched/J-Code In-Place	U.S.[1]
YUTIQ® 50 (sNDA) 6-month treatment for chronic non-infectious uveitis affecting the posterior segment			~45 patient 6-month study planned			WW
EYP-1901 - TKI Durasert™ 6-month wet AMD treatment	IND enabling studies					WW

[1] Alimera Sciences, Inc. owns worldwide rights to ILUVIEN® for DME and rights for YUTIQ® for non-infectious posterior uveitis in the EMEA with a royalty payable to Eyepoint.

PROPRIETARY OCULAR DELIVERY TECHNOLOGIES

Durasert™ and Verisome™: Proven, FDA Approved Technologies

Durasert™

Ocular insert for long-term delivery of small molecules

Approved products:

- YUTIQ® (2018, EyePoint)
- ILUVIEN® (2012, Alimera) - *DME*
- RETISERT ® (2005, B&L) – *Uveitis*
- VITRASERT® (1996, B&L) -*CMV retinitis*

Verisome™

Microsphere suspension short-term delivery of small and potentially large molecules

Approved products:

- DEXYCU® (2019, EyePoint)

2019: A TRANSFORMATIONAL YEAR



- YUTIQ® 50 *(6-month)* regulatory pathway reviewed with FDA with approval pathway clarified
- EYP-1901 – Durasert™ TKI for wet-AMD advanced into IND enabling studies
- Durasert™ and Verisome™ technologies positioned for partnering and organic pipeline growth
- YUTIQ® partnered in China
- Management team strengthened with commercial and development expertise

TWO COMMERCIAL PRODUCTS LAUNCHED IN 2019

EyePoint Pharmaceuticals

DEXYCU® (dexamethasone intraocular suspension) 9%

Postoperative inflammation following ocular surgery

- 33 dedicated KAMs targeting high-volume ambulatory surgical centers (ASCs)
- Permanent and specific J-Code with minimal reimbursement issues

0.18 mg YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg

Chronic non-infectious uveitis affecting the posterior segment of the eye

- 12 dedicated KAMs targeting uveitis specialists – increasing to 18 in 2020
- Permanent and specific J-Code effective as of October 1, 2019

DEXYCU® - Significant Market Opportunity ~$2B

U.S. Cataract Surgery Very Large and Growing

Step 1

Diseased lens is removed



Step 2

Intraocular lens is inserted



Step 3

Intraocular lens is positioned



- Steroids typically needed to prevent post-operative inflammation

3.8 Million*

Cataract Surgeries in 2018

- 8% annual growth rate in the U.S.
- Most performed surgery in the U.S.

Baby boomers; longer life expectancy with greater access to healthcare

Improvements in technology

Improved outcomes

* Based upon company estimates for 2018.
Source: imaged from the American Optometric Association.

DEXYCU® MARKET OPPORTUNITY

EyePoint Pharmaceuticals

Post-cataract Treatment Regimen Requires Multiple Daily Eyedrops



Up to 100 Drops Over Four Weeks

*Source: Vigamox/Besivance product labeling (not specifically indicated for this use, but are commonly prescribed for use).
**Source: Prolensa/Bromday product labeling (not specifically indicated for this use, but are commonly prescribed for use).

Physician Perspective

- Poor patient compliance with drops could lead to **poor outcomes**
- Patient call backs are time consuming and **disruptive to physician office**
- Patients/caregivers are **frustrated and confused with regimen**

DEXYCU®

EyePoint Pharmaceuticals

First and Only FDA-approved Single-dose, Sustained-release, Intracameral Steroid for the Treatment of Postoperative Inflammation Following Ocular Surgery

- Single dose (5µL) administered in the posterior chamber (behind the iris) at the end of surgery
- Encapsulated in bioerodible Verisome® technology for extended release of dexamethasone

Verisome® Technology



Dexamethasone

Detectable up to 22 days after single injection[1]

DEXYCU® Kit

DEXYCU® Placement



Suspension placed behind the iris

[1] Wong V. et al. Pharmacokinetic Study of 10090 in the Anterior Chamber of Rabbits (2013).
Note: Refer to the full DEXYCU® product label at www.eyepointpharma.com.

DEXYCU DEMONSTRATION

Please see video at company website:
https://eyepointpharma.com/case-study-series/

DEXYCU®

Statistically Significant Inflammation Reduction

Patients with Anterior Chamber Cells (ACC) Clearing at Each Visit



Note: Refer to the full DEXYCU® product label at www.eyepointpharma.com.

DEXYCU®

EYEPOINT PHARMACEUTICALS

IOP Elevation Versus Placebo Not Clinically Significant



Data on file. Phase III Study 13-04. Post hoc analysis.

DEXYCU®

Phase 3 Study – Safety Results

Safety, n (%)	Placebo N=80	517 mcg N=156
Any TEAE in Study Eye	51 (63.8)	72 (46.2)
Any Ocular SAE in Study Eye	0	0
Any Non-ocular SAE	4 (5.0)	4 (2.6)
Study Eye AEs Occurring in ≥5% of at Least One Active Treatment Group		
Intraocular Pressure Increased	7 (8.8)	21 (13.5)
Corneal Edema	8 (10.0)	12 (7.7)
Eye Pain	7 (8.8)	4 (2.6)
Anterior Chamber Inflammation	10 (12.5)	8 (5.1)
Dry Eye	0	6 (3.8)

Note: Refer to the full DEXYCU® product label at www.eyepointpharma.com.

DEXYCU® SALES PROCESS

Average Time (weeks) to Account Re-Order

1. **Introduce**
   Introduce DEYXCU and its clinical and safety data to target physician
2. **Educate**
   Educate the ASC where physician operates about DEXYCU profile
3. **Sample**
   Schedule a physician and staff DEXYCU trial and training
4. **Order**
   ASC places first order and files DEXYCU reimbursement claim
5. **Re-Order**
   Once reimbursement is confirmed, schedule additional patients for DEXYCU and provide ongoing ASC surgical support

DEXYCU® LAUNCH PROGRESS UPDATE

3Q19 Compared to 2Q19

207%

- Increase in customer orders

37%

- Repeat orders from ASCs

74%

- Volume from repeat orders

September 2019 Represented the Highest Volume Month for Repeat Orders to Date

ASC: Ambulatory Surgical Center

DEXYCU® CUMULATIVE ORDERS SINCE LAUNCH

Month Over Month Growth Accelerating

DEXYCU® month over month growth of cumulative orders averaged 62.5% in 3Q19



DEXYCU®

EYEPOINT PHARMACEUTICALS

Market Potential Based on Account Penetration thru 12/31/19



Value of Target Accounts

Value of Trained Accounts

Value of Current ASC Accounts Ordering

Value of Current ASC Accounts with 3+ Orders

ASC: Ambulatory Surgical Center
Data based on internal estimates

YUTIQ® Market

- Uveitis *is*:
  - Inflammation of the Uveal tract (iris, ciliary body, choroid), or adjacent structures (lens, retina, vitreous, optic nerve),
  - Acute or Chronic,
  - A precursor to severe vision loss or blindness
  - Often lifelong



~55K–120K

Patients in the U.S. with Chronic Non-infectious Posterior Segment Uveitis

- ~30,000 new cases of blindness per year in the U.S.
- 3rd leading cause of blindness in the U.S.

EYEPOINT PHARMACEUTICALS

YUTIQ® Is Designed to Deliver a Sustained Release of Fluocinolone for Patients with Chronic Noninfectious Posterior Uveitis for Up To 36 Months

Durasert Technology

Packaging

YUTIQ Placement



YUTIQ®

EYEPOINT PHARMACEUTICALS

Recurrence Rate at Six and Twelve Months vs Sham

Study 1 (Recurrence Rate at 6 and 12 Months)



Study 2 (Recurrence Rate at 6 and 12 Months)



■ YUTIQ ■ Sham*

* Sham includes standard of care.
Note: Refer to the full YUTIQ® product label at www.eyepointpharma.com

YUTIQ®

EyePoint Pharmaceuticals

Single Insert Reduced Probability of Uveitis Recurrence Through 36 Months

ITT Population



YUTIQ Median Time to First Recurrence: 1,051 Days

3 years

Note: Sham patients include patients that received rescue therapy.

YUTIQ®

Safety – Select Adverse Events

Safety, n (%)	YUTIQ® n=226	Placebo n=94
Visual Acuity Reduced	33 (15%)	11 (12%)
Macular Edema[1]	25 (11)	33 (35)
Uveitis	22 (10)	33 (35)
Conjunctival Hemorrhage	17 (8)	5 (5)
Eye Pain[2]	17 (8)	12 (13)
Hypotony of the Eye[3]	16 (7)	1 (1)
Anterior Chamber Inflamm.	12 (5)	6 (6)
Dry Eye	10 (4)	3 (3)

[1] Includes macular edema and cystoid macular edema
[2] Includes eye pain and procedural pain
[3] Includes hypotony, intraocular pressure decreased and procedural hypotension
Note: Refer to the full YUTIQ® product label at www.eyepointpharma.com

YUTIQ® LAUNCH PROGRESS UPDATE

3Q19 compared to 2Q19

EyePoint Pharmaceuticals

17%

- Increase of customer orders

53%

- Repeat customers

85%

- Volume from repeat orders

Continued Strong Reception of the YUTIQ® Product Profile from Uveitis Specialists

YUTIQ® CUMULATIVE ORDERS SINCE LAUNCH

YUTIQ® month over month growth of cumulative orders averaged 22% in 3Q19



KEY ACCESS AGREEMENTS TO EXPAND PRODUCT REACH

EyePoint Pharmaceuticals

VA | U.S. Department of Veterans Affairs

- DEXYCU® and YUTIQ® added to the Federal Supply Schedule
- Access to U.S. veterans and other federal agencies
- Nine Million VA beneficiaries added

vizient™

- Three-year agreement for DEXYCU®
- Vizient's network includes more than 50% of the nation's acute care providers, including 95% of the nation's academic medical centers, and more than 20% of ambulatory care providers

One of Largest Integrated Delivery Systems in the U.S.

- DEXYCU® available to its 8.5 million patients
- 2 year contract includes California, Washington, Georgia, Colorado and Mid-Atlantic states

AN EMERGING LEADER IN OPHTHALMOLOGY

EyePoint Pharmaceuticals

DEXYCU (dexamethasone intraocular suspension) 9%

Postoperative inflammation following ocular surgery

0.18 mg YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg

Chronic non-infectious uveitis affecting the posterior segment of the eye

- Transitioned into commercial growth company with the launches of YUTIQ® and DEXYCU® in Q1 2019
- Pipeline focused on innovative therapies improving standard of care in areas of unmet need, including wet AMD
- Focused on organic and inorganic product growth leveraging proprietary technologies and select product acquisition to build top-line revenue and expand pipeline
- Strategic focus to become go-to partner for commercialization in ophthalmology
- Veteran executive team with deep experience in commercial product launches and clinical development